Evidence map›Paper›PMID 42086782›Full record

ArticleNPJ precision oncology2026

An international framework for clinical translation of molecular classifiers in osteosarcoma.

Amanda E Marinoff, Michaela Nathrath, David S Shulman, Sarah B Whittle, Jovana Pavisic, Dimitrios Spentzos, Catherine M Albert, Joshua O Nash, Adam Shlien, Isidro Cortés-Ciriano and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Amanda E MarinoffDivision of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Michaela NathrathDepartment of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany, Klinikum Kassel, Department of Pediatric Oncology, Kassel, Germany.
David S ShulmanDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Sarah B WhittleTexas Children's Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Jovana PavisicDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dimitrios SpentzosDepartment of Orthopedic Surgery, Division of Orthopedic Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Catherine M AlbertDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, WA, USA.
Joshua O NashGenetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Canada.
Adam ShlienGenetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Canada.
Isidro Cortés-CirianoEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK.
Antonin MarchaisINSERM U1015, Gustave Roussy, Paris Saclay University, Villejuif, France; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Eunice López-FuentesDivision of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Christina CurtisStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
E Alejandro Sweet-CorderoDivision of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Richard GorlickDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Natalie DelRoccoDepartment of Population and Public Health Science Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Rashmi ChughDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
William D TapDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adrienne M FlanaganResearch Department of Pathology, Cancer Institute, University College London, London, UK.
Nathalie GasparINSERM U1015, Gustave Roussy, Paris Saclay University, Villejuif, France; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Brian D CromptonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Damon R ReedDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Katherine A JanewayDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Patrick J GroharDepartment of Pediatrics, Division of Pediatric Hematology Oncology, University of Michigan Medical School, CS Mott Children's Hospital, Ann Arbor, MI, USA.
J Andrew LivingstonDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan D RobertsDivision of Hematology, Oncology, and BMT, Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, USA. Ryan.Roberts@nationwidechildrens.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
National Institute for Health Research, UCLH Biomedical Research Centre, the UCL Experimental Cancer Centre, and the UCL / UCLH Biobank for Studying Health and Disease No specific grant numberNCI NIH HHS K12 CA260225NCI NIH HHS K12CA260225NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA128583Rally Foundation No specific grant numberThe Casper Colson philanthropic donation to the Sarcoma Program at the MGH Cancer Center and the Amy Chase McMahon Sarcoma Research Fund at the MGH Cancer Center No specific grant number
6 · The paper itself

Abstract

Despite well-recognized biological heterogeneity, osteosarcoma has been treated as a single disease for over four decades with minimal improvement in survival. Clinical features are inadequate for risk stratification, and no molecular classifiers guide therapy. An international working group evaluated candidate prognostic biomarkers for clinical translation. Pre-treatment circulating tumor DNA is positioned for clinical implementation, while additional classifiers warrant prospective validation. This work establishes a path to risk-adapted, biologically informed treatment.

Identifiers

PMID42086782
PMCPMC13346500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.